KPTINasdaqPharmaceutical Preparations

Karyopharm Therapeutics Inc. (KPTI) earnings date, market-implied expected move, and options open interest by expiry

0.09

−0.02 · −21.16%

post 0.09 −0.23%

Closed19:57 ET

Open0.11Volume16.6MMkt cap$2.0M

Day0.08 – 0.1117%52-wk0.08 – 10.990%

KPTI

Karyopharm Therapeutics Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Today

before open

est.Q3 FY26

Calendar

Next report

Last report

−1.97%

vs ±32.0% implied · ×0.06

shaded = implied · ▲▼ = realized

Aug 13 '26 · confirmed

Implied vs realized

Linked news

5dBMY · supplierBristol Myers Squibb posts Q3 net earnings $2,162 million, diluted EPS $1.05, revenue $13,069 million

News

Largest filed tie

13F top-10 QoQ

+27.94%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

99 managers

Top fund weight

0.01%

KPTI weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Karyopharm Therapeutics (KPTI) is expected to report on Nov 4 before open (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 13 '26confirmed±32.0%▼−1.97%×0.06

quarterimplied−35%0+35%realized×

Q2 FY26±32.0%▼−1.97%×0.06

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 3 close

0.29OI · 4 expiries · Nov 3 closeP/C open interest · Nov 20 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

2,230−13%Nov 2016d7,7740%

46+5%Dec 1844d0.114240%0.11

8,190−1%Jan 1572d12.626490%12.62

17,4880%Feb 19107d73.172390%73.17

ExpiryPutsCallsP/C

Nov 2016d2,230−13%7,7740%0.29

Dec 1844d46+5%4240%0.11

Jan 1572d8,190−1%6490%12.62

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ2 FY26

−200.48%as filednet margin · revenue −4.66% QoQ · −11.86% YoY

Revenue$33M−4.66%

Gross profit$32M96.75%−4.07%

Operating income−$23M−67.38%+15.82%

Pre-tax income−$67M−199.33%

Net income−$67M−200.48%−199.32%

Cost of revenue$1M−19.33%

Operating expenses$55M−9.27%

Tax$0−100.00%

Other expense−$44M−1118.47%

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 19:45 ET

Intraday

Event sensitivity

NFP ×0.98· ±4.5% vs ±4.6% · 10 releases

eventrelease day|move|up · n×base

NFPjobs report±4.5%6 of 10×0.98

CPROFcorporate profits±3.7%8 of 12×0.82

FOMCrate decision±3.6%10 of 24×0.80

PCEpersonal income & outlays±3.5%7 of 19×0.77

CPIconsumer prices±3.2%4 of 10×0.70

GDPgross domestic product±3.2%10 of 19×0.69

PPIproducer prices±2.7%3 of 10×0.58

Bar = avg |move| to ±5% · tick = ±4.6% avg day · ×base = |move| ÷ ±4.6% · min 6 releases

Earnings history

EPS -2.32 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 13 '26 · confirmed	-2.32	—
Q1 FY26	—	-1.24	—
Q3 FY25	—	-3.82	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod